Banzel has been approved for the adjunctive treatment of seizures linked with Lennox-Gastaut syndrome (LGS) in children 4 years and older and adults.
Eisai claims that its Banzel oral suspension is bioequivalent to currently marketed Banzel tablet formulation on a milligram per milligram basis.
The company said that it will launch the product in late March as a prescription drug.